We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Not Iconic

24 February 2021 By Robert Cyran

Icon is buying clinical-trials outsourcing rival PRA Health for a mix of cash and stock. The deal brings cost savings, expansion, and even tax savings on the combined business thanks to the acquirer’s Irish abode. But at 5%, the return on investment still isn’t attractive.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)